Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNST NASDAQ:DRNA NASDAQ:INVA NASDAQ:LGND NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ADRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINVAInnoviva$19.58+0.2%$19.63$16.67▼$22.00$1.24B0.47810,552 shs248,038 shsLGNDLigand Pharmaceuticals$165.94+0.3%$147.13$93.58▼$169.49$3.25B0.96150,562 shs115,470 shsPCRXPacira BioSciences$26.92+0.2%$24.38$13.42▼$27.64$1.21B0.42787,451 shs309,303 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVAInnoviva+0.93%-4.45%-6.55%-8.82%-1.31%LGNDLigand Pharmaceuticals-0.14%-0.21%+9.55%+47.07%+57.97%PCRXPacira BioSciences-0.96%+0.45%+8.39%+10.13%+104.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ADRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINVAInnoviva$19.58+0.2%$19.63$16.67▼$22.00$1.24B0.47810,552 shs248,038 shsLGNDLigand Pharmaceuticals$165.94+0.3%$147.13$93.58▼$169.49$3.25B0.96150,562 shs115,470 shsPCRXPacira BioSciences$26.92+0.2%$24.38$13.42▼$27.64$1.21B0.42787,451 shs309,303 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVAInnoviva+0.93%-4.45%-6.55%-8.82%-1.31%LGNDLigand Pharmaceuticals-0.14%-0.21%+9.55%+47.07%+57.97%PCRXPacira BioSciences-0.96%+0.45%+8.39%+10.13%+104.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation Pharmaceuticals 0.00N/AN/AN/ADRNADicerna Pharmaceuticals 0.00N/AN/AN/AINVAInnoviva 3.00Buy$42.75120.42% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.507.29% UpsidePCRXPacira BioSciences 2.71Moderate Buy$30.8314.60% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, DRNA, INVA, LGND, and CNST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.008/28/2025LGNDLigand PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$157.00 ➝ $206.008/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$155.00 ➝ $185.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$145.00 ➝ $162.007/25/2025PCRXPacira BioSciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ADRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77INVAInnoviva$370.23M3.30$3.43 per share5.65$11.03 per share1.76LGNDLigand Pharmaceuticals$167.13M19.29$1.59 per share103.15$43.95 per share3.74PCRXPacira BioSciences$705.85M1.71$4.28 per share6.28$16.86 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ADRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AINVAInnoviva$23.39M$0.3162.5712.51N/A10.44%18.67%9.92%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.34N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A10.47N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest PCRX, DRNA, INVA, LGND, and CNST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39DRNADicerna PharmaceuticalsN/A2.462.46INVAInnoviva0.362.642.44LGNDLigand PharmaceuticalsN/A5.455.21PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/ADRNADicerna Pharmaceuticals78.91%INVAInnoviva99.12%LGNDLigand Pharmaceuticals91.28%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%DRNADicerna Pharmaceuticals10.20%INVAInnoviva2.25%LGNDLigand Pharmaceuticals7.00%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionablePCRX, DRNA, INVA, LGND, and CNST HeadlinesRecent News About These Companies51,764 Shares in Pacira BioSciences, Inc. $PCRX Bought by Caxton Associates LLPSeptember 12, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 9, 2025 | marketbeat.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comBridgeway Capital Management LLC Buys 69,744 Shares of Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comAlyeska Investment Group L.P. Takes $32.51 Million Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comRafferty Asset Management LLC Takes $251,000 Position in Pacira BioSciences, Inc. $PCRXSeptember 6, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comPDT Partners LLC Has $5.14 Million Stock Position in Pacira BioSciences, Inc. $PCRXSeptember 3, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLCSeptember 1, 2025 | marketbeat.com9,457 Shares in Pacira BioSciences, Inc. $PCRX Acquired by FORA Capital LLCSeptember 1, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Holdings Lifted by Walleye Capital LLCAugust 30, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Wellington Management Group LLPAugust 29, 2025 | marketbeat.comQuantbot Technologies LP Purchases 24,102 Shares of Pacira BioSciences, Inc. $PCRXAugust 28, 2025 | marketbeat.comMartingale Asset Management L P Takes Position in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Holdings in Pacira BioSciences, Inc. $PCRXAugust 27, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Holdings in Pacira BioSciences, Inc. $PCRXAugust 26, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Invesco Ltd.August 25, 2025 | marketbeat.comNuveen LLC Makes New Investment in Pacira BioSciences, Inc. $PCRXAugust 24, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, DRNA, INVA, LGND, and CNST Company DescriptionsConstellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Dicerna Pharmaceuticals NASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Innoviva NASDAQ:INVA$19.58 +0.03 (+0.15%) As of 01:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ligand Pharmaceuticals NASDAQ:LGND$165.94 +0.42 (+0.25%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Pacira BioSciences NASDAQ:PCRX$26.92 +0.06 (+0.24%) As of 01:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
